274 results about "Hematological sample" patented technology

The invention discloses an SERS (Surface Enhanced Raman Scattering) detection method for paclitaxel drug concentration in blood of a breast cancer patient, and belongs to the technical field of detection. The method comprises the following steps: performing acetonitrile two-step precipitation centrifugal treatment on a blood sample to obtain a detection sample; the method comprises the following steps: constructing a high-sensitivity SERS substrate (the volume ratio of gold nanoparticles to ethanol is 1: (90-100), and a film is formed on a water-cyclohexane interface) through self-assembly of gold nanoparticles on a liquid-liquid interface; the method comprises the following steps: dropwise adding a sample into a substrate, and detecting characteristic peaks of 1024cm <-1 > and 1053cm <-1 > by using a portable Raman spectrometer (785nm, 30mW, 0.5 s); and calculating the paclitaxel concentration in combination with a pre-established quantitative curve. The method is easy and convenient to operate and suitable for clinical bedside rapid monitoring.

An apparatus and method for measuring clotting capacity of a patient's blood comprises a probe having a wetted portion, a well to receive a blood sample to contact the wetted portion, a spring element intermediate the wetted portion and a probe support, and a sensor to determine the displacement of the wetted portion resulting from a displacing force imparted to the wetted portion by a clotting blood sample in the well. Embodiments of the apparatus of the present invention may include a variable capacitance displacement sensor, an eddy current variance sensor, a microelectromechanical sensor and an optical instrument. Embodiments of the apparatus may include a current source. The present invention enables reliable detection of mitochondrial dysfunction and sepsis in a blood sample. Embodiments of the apparatus of the invention may be portable. A probe used in such embodiments may be disposable.

The invention relates to a blood rheological parameter online monitoring and thrombus risk assessment method, which comprises the following steps: introducing a blood sample into a microfluidic channel with a periodic geometric mutation structure, applying unsteady shear disturbance through a piezoelectric oscillation device, inducing blood to enter a non-equilibrium rheological state, and exciting a microcosmic coagulation tendency; the red blood cell aggregation behavior, the cell layer slippage phenomenon and the plasma shearing stability are recognized through the photo-thermal interference technology, and the rheological structure layer differentiation characteristics in blood are obtained; the blood subjected to shear disturbance is guided to a micro-channel high-pressure area provided with a flow-limiting threshold structure, and pressure mutation and microcoacervation nucleation generation behaviors induced by local stress disturbance are detected through a nanoscale piezoresistive sensor so as to identify sub-phase change response characteristics of the blood; and constructing a rheological instability index system on the basis of physical response signals obtained by shear disturbance, slippage and variable response, and when linkage abnormity of any two indexes is detected, judging that a high-risk event of thrombosis occurs and outputting a risk prompt signal.

The invention relates to the technical field of spectral component measurement, in particular to a high performance liquid chromatography detection method of glycosylated hemoglobin for a diabetic pregnant woman. According to the method, high performance liquid chromatograms at different temperatures are obtained, the chromatograms are processed through EMD mode decomposition, screening is carried out according to peak value characteristics, and the IMF component of the hemoglobin component is determined. Matching the IMF components of the hemoglobin components at different temperatures, and obtaining the hemoglobin type of each IMF component of the hemoglobin components according to the obtained temperature matching components and the retention time of the middle components. And counting the content of each hemoglobin type at all temperatures to obtain the content of each hemoglobin type in the blood sample. According to the method, errors in detection are eliminated through chromatographic detection and data statistics, and a more accurate detection result of glycosylated hemoglobin of a diabetic pregnant woman is obtained.

In the agglutinated platelet parameter detection method and the identification AI training method thereof, a blood sample is preprocessed, and a microscopic examination sample is obtained and tiled; standing the platelets to sink to the bottom; shooting to obtain a microscopic examination sample image; according to the method, normal platelets and agglutinated platelets are identified and labeled, a labeled picture is obtained for AI training, an obtained AI feature data set A comprises normal platelet features, and an AI feature data set A comprises agglutinated platelet features. Identifying a microscopic examination sample image by using an AI identification algorithm, identifying agglutinated platelets in the blood sample in a selected area S1 of the image, and obtaining the total number NUMS1 of the agglutinated platelets in the blood sample in the selected image; and the AI recognition algorithm recognizes the agglutinated platelets in the blood sample according to the agglutinated platelet feature data set. The recognition of the agglutinated platelets is completed by utilizing advanced AI computing power, so that the analysis of the agglutinated platelets is more efficient and more accurate, and the dimension of platelet function analysis based on images is expanded.

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

The invention relates to the technical field of detection, and discloses a detection method and application of p-phenylenediamine antioxidants and quinone derivatives thereof, and the method comprises the following steps: taking a blood sample or a tissue sample, placing in a centrifuge tube, adding a recovery rate indicator solution and a glutathione solution, adding an extraction solvent, extracting twice, and combining the two solutions; centrifuging for 4-6 minutes at the speed of 3000-4500 rpm after each extraction, and combining the two extracts to obtain an extract to be detected; concentrating the to-be-detected extracting solution to be dry under soft nitrogen to obtain a to-be-detected concentrated dry substance; purifying with / without an HLB column; further concentrating the eluent, adding acetonitrile for redissolving, passing through an organic filter membrane, putting into a small sample injection bottle, and concentrating again; adding an internal standard solution to a constant volume to obtain a to-be-detected sample solution; and finally, detecting the sample solution to be detected by using an ultra-high performance liquid chromatography system and a mass spectrometer. According to the invention, the blank of no corresponding detection method for various PPDs and PPD-Qs in human blood and tissues is filled up.

A system and a method for measuring adhesion of blood cells in microfluidic channels are disclosed. The system includes a device having one or more microfluidic channels configured to adhere a plurality of diseased red blood cells (RBCs) of a blood sample on an interior surface of the one or more microfluidic channels. Further, the system includes at least one imager configured to generate one or more digital holography images or videos of the plurality of diseased RBCs adhered to the interior surface of the one or more microfluidic channels. Further, at least one processor is operationally coupled to the at least one imager and configured to receive the one or more digital holography images or videos and analyze the generated one or more digital holography images or videos to quantify adhesion of the plurality of diseased RBCs to the interior surface of the one or more microfluidic channels.

The utility model relates to the field of medical instruments, and discloses a cardiovascular medical instrument half in-vitro blood compatibility testing device which comprises testing equipment, a placing groove is formed in the right side of the front surface of the testing equipment, a second rectangular groove is formed in the inner wall of the placing groove, and a clamping assembly is arranged on the inner wall of the second rectangular groove. A limiting assembly is arranged on the front surface of the clamping assembly, a third rectangular groove is formed in the bottom end of the inner wall of the containing groove, an adjusting assembly is arranged on the inner wall of the third rectangular groove, the clamping assembly comprises a sliding block, the rear surface of the sliding block is slidably connected to the inner wall of the second rectangular groove, and a platform is fixedly connected to the front surface of the sliding block. The inner wall of the bottom end of the platform is rotationally connected with a rotating plate. According to the blood sample detection device, by arranging the clamping assembly, a blood sample can be fixed, the detection stability is improved, meanwhile, under the cooperation of the limiting assembly, the clamping assembly can be prevented from loosening in the clamping process, and the clamping stability is improved.

The invention relates to the technical field of health management systems, and provides a pituitary hormone level monitoring-based health management system, which comprises a multi-source data acquisition terminal, a hormone analysis terminal, an intelligent decision center terminal and a visual interaction terminal, the multi-source data acquisition terminal is used for regularly acquiring a blood sample and work and rest rule information of a user; the hormone analysis terminal is used for measuring the hormone concentration of a specified hormone type in the blood sample and generating hormone time sequence information; the specified hormone type is preset by an administrator or is set according to health management requirements; the intelligent decision center terminal is used for performing individual health state assessment of the user according to the hormone time sequence information and the work and rest rule information, and generating health state assessment information and health strategy suggestions; and the visual interaction terminal is used for displaying the health state evaluation information and the health strategy suggestions. The method has the effect of improving the accuracy of health management.

A sample measuring apparatus according to an embodiment may be a sample measuring apparatus for measuring a platelet aggregation function of a blood sample. The apparatus may include: a detection section configured to measure optical information of platelet rich plasma and platelet poor plasma prepared from a blood sample; a control section configured to acquire information on a platelet aggregation function of the blood sample based on optical information of platelet rich plasma and platelet poor plasma; and a display configured to display information on a platelet aggregation function. The controller is configured to obtain evaluation information on suitability of the platelet-rich plasma as a sample based on a measurement result of the platelet-rich plasma by the detection portion, and display the evaluation information on the display.

The invention provides improved methods for enriching targeted genomic regions of interest to be analyzed by multiplexed parallel sequencing. The methods of the invention utilize a pool of TArget Capture Sequences (TACS), wherein the pool comprises a plurality of TACS families, each member of a family binding to the same target sequence but with different start and / or stop positions on the sequence (i.e., staggered binding of the family members to the target sequence) to thereby enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. The methods of the invention can be used for a variety of clinical purposes, including non-invasive prenatal testing for chromosomal abnormalities, for example using a maternal blood sample or a sample of fetal cells, assessment of maternal and paternal carrier status for genetic disorders and detection of tumor biomarkers (e.g., liquid biopsy). Kits for carrying out the methods of the invention are also provided.

The invention belongs to the technical field of biological extraction, and discloses a separation method for improving the yield of human lymphocytes. The method comprises the following steps: collecting blood cells, diluting the blood cells, obtaining lymphocytes and recovering the lymphocytes. The method is characterized in that a blood cell diluent is prepared and comprises human serum albumin, EDTA-2Na (Ethylene Diamine Tetraacetic Acid-2Na) and a calcium-magnesium ion-free PBS (Phosphate Buffer Solution). The method is applied to lymphocyte separation, the osmotic pressure of cells in the separation process can be improved, the normal form of the cells can be maintained, the viscosity between the cells can be reduced, cell adhesion can be prevented, meanwhile, the part which is adhered to form a membrane layer or a cell cluster is separated twice, the lymphocyte separation yield is remarkably increased, and the method is simple to operate and easy to implement. The realization is easy. The method is especially suitable for blood samples of people with immune system diseases, blood samples and blood viscous samples of old and sick people, non-fresh blood samples and the like.

The invention discloses a direct counting method and device for detecting the number of fluorescence-labeled rare abnormal cells in a blood sample. Aiming at the problem that direct counting of low-abundance cells is difficult to realize in a conventional blood container by a traditional detection means, the method realizes rapid and direct counting of rare abnormal cells by performing narrow-band filtering, efficient collection and high signal-to-noise ratio detection on a fluorescence signal emitted by a static blood sample. The device comprises a lighting source module, an exciting light and emitted light narrow-band filtering module, a light beam collimation and beam expansion module, a sample bearing module, an emitted light collection and detection module and a data processing and counting module. Accurate counting of the extremely-low-abundance fluorescence labeling abnormal cells can be completed in a conventional transparent container without flow sorting or complex treatment of a blood sample, and the method has the advantages of being easy and convenient to operate, high in detection speed, suitable for clinical screening and the like.

A kit for quantitative analysis of C-reactive protein (CRP) according to an embodiment of the present application may comprise: a first composition comprising a hemolytic agent for hemolyzing at least a portion of blood cells in a blood sample; and a second composition comprising an anti-CRP antibody for the antigen-antibody reaction of the CRP contained in the hemolyzed sample. The CRP quantitative analysis kit of the present application can provide a stabilizer which enables a solid-phase dry anti-CRP antibody to be sufficiently redissolved to participate in an immune reaction, so that quantitative analysis of CRP can be highly accurately and accurately performed in a wide concentration range, and storage stability is improved.

A blood leukocyte recognition AI training method comprises the following steps: diluting blood to obtain a blood sample; flatly spreading the blood sample to enable white blood cells to suspend in the liquid and to present a natural state; shooting the blood sample to obtain a picture; carrying out AI training by using the obtained pictures to obtain a leukocyte AI feature data set A; aI training is carried out on the leukocyte picture in the suspension state to obtain an AI feature data set A, and AI detection of blood in the suspension state can be effectively supported and recognized. The AI feature data set A is obtained by carrying out AI training on the leukocyte picture in the suspension state, AI detection of blood in the suspension state can be effectively supported and recognized, and the AI recognition function in a new-mode blood detection technology is effectively supported by tiling and imaging blood cells.

To provide methods for preparing novel immunoregulatory macrophage cells which are useful in the treatment of different immunological and non-immunological diseases and conditions; resulting macrophage cells; and pharmaceutical compositions comprising macrophage cells.SOLUTION: A method for preparing an immunoregulatory macrophage cell is provided, the method comprising: (a) isolating CD14 positive monocytes from a blood sample of a subject; (b) culturing the monocytes in a gas-permeable bag in a culture medium containing (i) M-CSF and / or GM-CSF, and (ii) a CD16 ligand; (c) contacting the cells with IFN-γ; and (d) obtaining the immunoregulatory macrophage cell from the culture medium.SELECTED DRAWING: Figure 10

The utility model relates to a device for determining the concentration of certain ions in a blood sample, comprising: a top layer of a membrane (1) capable of filtering out all components in the sample other than plasma; an intermediate layer of glass fibers (2) coated with an ion-selective complex comprising an ionophore (10), a cation exchanger (11) and a dye (12) for promoting the exchange between the certain ions (13) in the plasma and the dye (12); and a bottom layer comprising a millifluid channel (4) along which the dye can travel, where a distance (16) traveled by the dye is indicative of the concentration of the certain ions in the sample.

The application relates to the technical field of blood drug concentration detection, and discloses a blood drug concentration analysis method based on mass spectrometric detection, which comprises the following steps: adopting microfluidic technology in combination with solid-phase extraction to pretreat a blood sample to obtain a concentrated solution, so as to remove interfering components and concentrate target drug molecules; according to the physicochemical properties of the target drug molecules, the concentrated solution is selected to flow through a biosensor or is directly introduced into a chromatographic unit, and the target drug molecules in the liquid phase are converted into gas-phase ions when flowing through the biosensor; chromatography-mass spectrometry is adopted to detect the gas-phase ions or the concentrated solution, so as to obtain mass spectrum data; a machine learning model is used to analyze the spectrum data, to identify the drug types and calculate the concentration of the target drug molecules, and to generate an analysis report. The method is suitable for target drugs with different physicochemical properties, simplifies the detection process, and improves the applicability and accuracy of detection.

In various embodiments, disclosed herein are methods of assessing therapeutic efficacy of an anticoagulant. Preferably, the method comprising providing a blood sample; perfusing the blood sample over a surface coated with collagen or immobilized rTF; measuring platelet aggregation and fibrin deposition on the surface coated with collagen or immobilized rTF; and assessing therapeutic efficacy of the anticoagulant based on the volume of platelet aggregates and / or deposited fibrin.

The present application relates to the technical field of tumor cell detection chip, in particular to a kind of based on inertial microfluidic tumor cell mechanical property detection device and method, the present application adopts sine microfluid channel inertial focusing cell, and the mechanical property detection of cell multiple deformation in channel is carried out by high-speed camera.The cell suspended in PBS is subjected to the combined action of inertial force and dean force in sine microfluid channel, and the single-column focusing of cell can be realized in a wide flow rate range, and the recognition accuracy of optical detection is improved.Cell is subjected to shear force, tensile force and wall collision in microfluid channel and generates three deformations, and different types and sizes of force make cell produce different degrees and shapes of deformation.The size, roundness, deformation and circumscribed rectangle size of cell in different deformations are extracted, and the classification model of species is trained using machine learning method, to identify cell species.The present application is suitable for the detection of various cells in blood samples and biological particles in other biological samples.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The present invention relates to the field of biological diagnosis technology, and in particular to a diagnostic kit for triple-negative thrombocythemia based on platelet RNA, protein and plasma cytokines, including a classification joint module, which is constructed by integrating characteristic markers of platelet transcriptome, platelet proteome and plasma cytokine group, wherein the characteristic marker is selected from the platelet transcriptome, the platelet proteome and the plasma cytokine group in the biomarker detection data. The biomarker with a SHAP value greater than 0.01. The diagnostic kit provided by the present invention can effectively identify characteristic markers related to triple-negative ET, providing strong support for precision medicine and clinical diagnosis. At the same time, the diagnostic kit performs multiple tests on platelet RNA, protein and plasma cytokines through a single blood sample, which reduces the economic burden of patients and has broad clinical application prospects.

The invention relates to the technical field of biological detection, and discloses a sample diluent and application thereof and a kit, pure water is taken as a solvent, and the sample diluent at least comprises 15-80 g / L of soluble sodium salt, 0.05-0.5 g / L of soluble potassium salt, 8-15 g / L of amino acid, 0.2-1 g / L of goat serum albumin, 0.2-1 g / L of surfactant, 0.5-2 g / L of trehalose and 0.5-2 mL / L of Proclin-300 according to concentration, the sample diluent provided by the invention can weaken non-specific binding of impurities in a blood sample and a target analyte, so that the accuracy of a final detection result is improved.

The invention discloses a control method of blood processing chips. The blood processing chips are loaded in a centrifugal machine; upper plasma and red blood cells are separated based on first centrifugation of blood, and normal saline enters a mixing area; the centrifugal machine stops working, the red blood cells sequentially enter a siphon flow channel and sequentially trigger second-time centrifugation and third-time centrifugation, the siphon flow channel is in an open state, and the red blood cells enter the mixing area from the red blood cell quantifying area; the red blood cells are layered with normal saline in the mixing area due to centrifugal action; carrying out fourth centrifugation, carrying out positive and negative rotation of the centrifugal machine, carrying out re-uniform mixing through oscillation, carrying out red blood cell resuspension, and carrying out multiple times of separation on the blood along the vertical direction; rotating the centrifugal tray by 90 degrees, standing for 3 minutes, and enabling the resuspension in the uniform mixing area to enter a capillary quantitative flow channel; the blood processing chip is matched with the detection card and judges the blood type, and the blood sample, the normal saline and the reverse red blood cells are located in the blood processing chip and are separated for multiple times in the blood processing chip.

The present disclosure presents glucose sensing methods and systems. One such system comprises an electrospun-nanofibrous-membrane (ENFM)-based amperometric glucose sensor integrated on a silicon chip, in which the glucose sensor has a working electrode, a reference electrode, and a counter electrode, wherein the working electrode comprises an ENFM-based sensing electrode. The system further comprises a potentiostat circuit integrated on the silicon chip such that the potentiostat circuit comprises a voltage control unit to control a voltage difference between the working electrode and the reference electrode and a transimpedance amplifier to measure a current flow between the working electrode and the counter electrode, in which a strength of the current flow corresponds to an amount of glucose present in a sample of blood on the glucose sensor.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The present invention provides a novel means usable for predicting a therapeutic effect of a combination therapy of an IL-6 inhibitor and a chemotherapy in a pancreatic cancer patient, said means being characterized by use of blood CD8-positive effector memory T cells as a biomarker. Specifically, in order to predict a therapeutic effect of a combination therapy of an IL-6 inhibitor and a chemotherapy in a pancreatic cancer patient, (i) the level of CD8-positive effector memory T cells that are contained in a blood sample which is collected from the pancreatic cancer patient is measured and (ii) when the level of the CD8-positive effector memory T cells is high, it is determined that the therapeutic effect yielded by the combination therapy is high.

The invention provides a data processing device for pulmonary tuberculosis disease risk assessment and application thereof. The data processing device provided by the invention comprises a memory, a processor and a computer program stored on the memory, and the processor executes the computer program to realize the following steps: receiving gene expression quantity data in a blood sample of a subject, performing pulmonary tuberculosis disease risk grouping on the subjects according to the gene expression quantity data; the gene at least comprises an aspartate beta-hydroxylase structural domain 2 gene (ASPHD2). The data processing device provided by the invention can be used for evaluating or assisting in evaluating the pulmonary tuberculosis disease risk of the subject, improves the accuracy of risk evaluation, and has a relatively high clinical application value.

A cell morphology analysis device, a cell identification method and a storage medium, wherein a digital camera captures a cell image of a blood sample under a low-power objective lens, a processor identifies and locates suspected preset type cells in the cell image, obtains an identification result, determines the located number of suspected preset type cells based on the identification result and the target number, and after completing the identification and positioning of the located number of suspected preset type cells, the digital camera captures the identified and located suspected preset type cells under a high-power objective lens, and the processor then identifies whether the captured suspected preset type cells are preset type cells, so as to count the number of preset type cells captured under the high-power objective lens and obtain a statistical value. When the statistical value satisfies: target number ≤ statistical value, the capture is stopped. At the end, the processor identifies at least the target number of preset type cells to meet clinical needs for preset type cells.